News
-
Reckitt Benckiser Pharmaceuticals will co-develop a unit-dose naloxone nasal spray for the reversal of opioid overdoses with Kentucky-based AntiOp, the company has announced. The only detail of the deal that was released is that the… Read more . . .
-
Kamada has announced that preliminary results from its Phase 2/3 pivotal trial of its inhaled Alpha-1 Antitrypsin (AAT) therapy showed no difference between inhaled AAT and placebo in “time to first moderate or severe exacerbation,”… Read more . . .
-
As part of an interim management statement, Skyepharma has said that the launch of its Flutiform fluticasone/formoterol MDI in Spain could take place by the end of 2014, triggering a milestone payment of €2.0 million.… Read more . . .
-
Pharmaterials, Reading, UK. The jobholder will be part of the inhalation department and will be responsible for supporting projects related to Pharmaceutical Development and Manufacturing operations. The job holder must be well organized, dynamic and… Read more . . .
-
Apotex says that it launched a generic budesonide nasal spray in the US on May 13, 2014 following the previous day’s approval of the product by the FDA. The new product, with a strength of… Read more . . .
-
At the recent Orlando Inhalation Conference, Bing Li of the FDA’s Division of Bioequivalence in the Office of Generic Drugs (OGD) of the Center for Drug Evaluation and Research (CDER) provided a list of frequently… Read more . . .
-
Teva has announced the FDA’s acceptance of its supplemental NDA for a low-dose formulation of QNASL beclomethasone dipropionate HFA nasal spray for the treatment of allergic rhinitis in children aged 4-11. The FDA approved QNASL… Read more . . .
-
Perrigo has announced that it has begun shipping its generic version of Astepro azelastine nasal spray after the ANDA it submitted in partnership with Impax Laboratories received final approval from the FDA. In January 2012,… Read more . . .
-
GlaxoSmithKline and Theravance have announced that they have received marketing authorization for the Anoro Ellipta umeclidinium/vilanterol DPI for the treatment of COPD in Europe. The EMA’s Committee for Medicinal Products for Human Use (CHMP) issues… Read more . . .
-
The Medicon Valley Inhalation Consortium (MVIC) has announced the addition of four new member companies, bringing the total to 24. The newly added companies are OM Projekt, Lastow Consulting, Competitive Intelligence Solutions (CIS), and AB… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA